



Aalborg Universitet

AALBORG UNIVERSITY
DENMARK

Stroke Prevention, Evaluation of Bleeding Risk, and Anticoagulant Treatment Management in Atrial Fibrillation Contemporary International Guidelines

Proietti, Marco; Lane, Deirdre A; Boriani, Giuseppe; Lip, Gregory Y H

Published in:
Canadian Journal of Cardiology

DOI (link to publication from Publisher):
[10.1016/j.cjca.2019.02.009](https://doi.org/10.1016/j.cjca.2019.02.009)

Creative Commons License
CC BY-NC-ND 4.0

Publication date:
2019

Document Version
Accepted author manuscript, peer reviewed version

[Link to publication from Aalborg University](#)

Citation for published version (APA):
Proietti, M., Lane, D. A., Boriani, G., & Lip, G. Y. H. (2019). Stroke Prevention, Evaluation of Bleeding Risk, and Anticoagulant Treatment Management in Atrial Fibrillation Contemporary International Guidelines. *Canadian Journal of Cardiology*, 35(5), 619-633. <https://doi.org/10.1016/j.cjca.2019.02.009>

General rights

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal -

Take down policy

If you believe that this document breaches copyright please contact us at vbn@aub.aau.dk providing details, and we will remove access to the work immediately and investigate your claim.

Accepted Manuscript



Stroke Prevention, Evaluation of Bleeding Risk and Anticoagulant Treatment Management in Atrial Fibrillation Contemporary International Guidelines

Marco Proietti, MD, Deirdre A. Lane, PhD, Giuseppe Boriani, MD PhD, Gregory Y.H. Lip, MD

PII: S0828-282X(19)30116-3

DOI: <https://doi.org/10.1016/j.cjca.2019.02.009>

Reference: CJCA 3181

To appear in: *Canadian Journal of Cardiology*

Received Date: 11 December 2018

Revised Date: 15 February 2019

Accepted Date: 15 February 2019

Please cite this article as: Proietti M, Lane DA, Boriani G, Lip GYH, Stroke Prevention, Evaluation of Bleeding Risk and Anticoagulant Treatment Management in Atrial Fibrillation Contemporary International Guidelines, *Canadian Journal of Cardiology* (2019), doi: <https://doi.org/10.1016/j.cjca.2019.02.009>.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

1 **Stroke Prevention, Evaluation of Bleeding Risk and Anticoagulant Treatment**
2 **Management in Atrial Fibrillation Contemporary International Guidelines**

3
4 **Short Title:** International AF Guidelines

5
6 Marco Proietti^{1,2} MD, Deirdre A. Lane^{3,4} PhD,

7 Giuseppe Boriani^{5*} MD PhD, Gregory Y.H. Lip^{3,4*} MD

8
9 ¹Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milan, Italy; ²Department of
10 Internal Medicine and Medical Specialties, Sapienza-University of Rome, Rome,
11 Italy; ³Liverpool Centre for Cardiovascular Science, University of Liverpool and
12 Liverpool Heart & Chest Hospital, Liverpool, United Kingdom; ⁴Aalborg Thrombosis
13 Research Unit, Department of Clinical Medicine, Aalborg University, Aalborg,
14 Denmark; ⁵Department of Biomedical, Metabolic and Neural Sciences, University of
15 Modena and Reggio Emilia, Policlinico di Modena, Modena, Italy.

16
17 *joint senior authors.

18
19 **Corresponding Author:**

20 Professor Gregory YH Lip:

21 E-mail: gregory.lip@liverpool.ac.uk

22

1 SUMMARY

2 In contemporary international guidelines on the management of atrial fibrillation,
3 there is general agreement about the baseline evaluation of thromboembolic and
4 bleeding risk and preferential use of NOACs. Notwithstanding the broad agreement,
5 more data are needed about management of specific AF sub-populations. The need
6 for an integrated approach and holistic management is highlighted in the more
7 recently published guidelines.

1 ABSTRACT

2 In recent years the management of AF patients has progressively and substantially
3 changed due to the introduction of new treatments and the availability of new data
4 regarding the epidemiology and clinical management of these patients. In the last
5 two years alone, there have been seven new guidelines or guideline updates that
6 have been published, introducing new recommendations and significantly revising
7 previously published ones. Two updates for Canadian guidelines were published in
8 2016 and 2018, while guidelines from the European Society of Cardiology in 2016,
9 Asia Pacific Heart Rhythm Society in 2017, National Heart Foundation of
10 Australia/Cardiac Society of Australia and New Zealand, American College of Chest
11 Physicians and Korean Heart Rhythm Society in 2018 have been published. This
12 narrative review aims to provide a comparison of these contemporary international
13 guidelines, with particular attention on the evaluation of thromboembolic and
14 bleeding risks and management of OAC therapy.

15 From the analysis of contemporary guidelines on the management of atrial
16 fibrillation, a general agreement is evident about the baseline evaluation of
17 thromboembolic and bleeding risk, as well as a preference for the use of NOACs.
18 Also, regarding the concomitant use of OAC and antiplatelet drugs in patients with
19 acute coronary syndromes, undergoing elective percutaneous coronary intervention,
20 catheter ablation and cardioversion procedures, all the guidelines agree on the
21 general principles and are supported by evidence. More data are still needed to
22 better substantiate recommendations for specific AF sub-populations. The need for
23 an integrated approach and holistic management is highlighted in the more recently
24 published guidelines.

25

1 Introduction

2 In the last ten years, clinical practice on stroke prevention in patients with atrial
3 fibrillation (AF) has markedly changed¹. The introduction of non-vitamin K antagonist
4 oral anticoagulants (NOACs) as an alternative to the vitamin K antagonists (VKAs)²,
5 has significantly increased the prescription and use of oral anticoagulant (OAC)
6 therapy in AF patients, as demonstrated by several epidemiological and
7 observational studies³⁻⁶.

8
9 There has been much interest in expanding the understanding of AF
10 pathophysiology, epidemiology and natural history, leading to an increasing number
11 of papers on AF being published [Figure 1]. The deluge of data available has
12 informed how several new issues are managed and have led to a change in clinical
13 practice regarding patients with AF, both regarding the evaluation and reduction of
14 thromboembolic risk as well as the general management of such patients. There is
15 also an increasing focus on how the risk of cardiovascular and all-cause death is
16 becoming an even more relevant issue in clinical history and clinical management of
17 these patients⁷⁻¹⁰. This change in the risk profile has led to appeals for a new
18 approach to the management of AF patients, involving a more integrated and holistic
19 approach^{11,12}.

20
21 In the last two years alone, there have been several new guidelines or guideline
22 updates that have been published, introducing new recommendations and
23 significantly revising the previously published ones¹³⁻¹⁹. This narrative review aims
24 to provide a comparison of these contemporary international guidelines or updates,

1 with particular attention to the evaluation of thromboembolic and bleeding risks and
2 management of OAC therapy.

3

4 **Overview and General Features of Contemporary International Guidelines**

5 We provide an overview of the new guidelines published in the last two years^{13–19}.

6 General characteristics of these new guidelines are reported in Table 1.

7

8 In 2016 the Canadian Cardiovascular Society (CCS) published an update¹³ to their
9 2010 AF clinical guidelines²⁰, while in 2016 the European Society of Cardiology
10 (ESC) published their new guidelines¹⁴, completely revising the previous main
11 guideline from 2010 and the 2012 focused update^{21,22}. In 2017, the Asia Pacific
12 Heart Rhythm Society (APHRS) published their guidelines on stroke prevention in
13 AF¹⁵. Finally, three entirely new guidelines in 2018 from National Heart Foundation
14 of Australia (NHFA)/Cardiac Society of Australia and New Zealand (CSANZ)¹⁶, from
15 the American College of Chest Physicians (ACCP)¹⁷ and Korean Heart Rhythm
16 Society (KHRS)¹⁹ with a second focused updated from the CCS guidelines¹⁸ were
17 published in 2018.

18

19 Five out of seven guidelines performed a systematic search of currently available
20 evidence based on a structured and established technique used in evidence-based
21 practice to frame and answer clinical or health related questions, the PICO
22 (Population, Intervention Comparison, Outcomes) both in its original or modified form
23 or the clinical questions model^{13,14,16–18}. Conversely, the APHRS and KHRS
24 guidelines were substantially based on expert consensus review^{15,19}. The 'Grading of
25 Recommendations, Assessment, Development and Evaluations' (GRADE)

1 methodology was used to evaluate the quality of scientific evidence in four of the
2 seven guidelines^{13,16-18}. Heterogeneity was evident in the grading of the strength of
3 the recommendations and quality of evidence, with APHRS guidelines not explicitly
4 grading their recommendations¹⁵ and with KHRS ones only grading a limited number
5 of recommendations¹⁹. Concerning conflict of interests, only the ESC, NHFA/CSANZ
6 and ACCP guidelines^{14,16,17} provided detailed disclosure of direct, indirect and
7 potential conflict of interests, with the latter, ACCP, prohibiting voting on those issues
8 for which an author reported a potential conflict of interest.

9
10 While we found a considerable variability regarding the classification of clinical types
11 of AF, in particular related to the use of new onset/first detected AF and long-
12 standing persistent AF, there was a substantial agreement across the various
13 guidelines regarding the definition of non-valvular AF which is generally considered
14 as the absence of mitral stenosis, even though some guidelines specifically stated
15 the differential rheumatic or non-rheumatic origin and the degree of disease, and of
16 mechanical heart valve. Notwithstanding, two guidelines did not assess the
17 definition^{15,19}.

19 **Evaluation of Thromboembolic Risk Evaluation and OAC Prescription**

20 When evaluating thromboembolic risk (Table 2), most guidelines recommended the
21 use of CHA₂DS₂-VAsC score^{14-17,19}, although the NFHA/CSANZ guidelines used a
22 modified CHA₂DS₂-VA score, that no longer consider the role of sex category in
23 guiding the baseline OAC prescription¹⁶. This modification of the CHA₂DS₂-VAsC
24 score in the NFHA/CSANZ guidelines was justified by differential cut-offs for male
25 and female AF patients or recommendations to exclude the sex category in the

1 evaluation by other guidelines (Table 2)^{14,15,17,19}. The 5 guidelines using CHA₂DS₂-
2 VASc score, recommend prescribing OAC therapy in all patients with at least 1 non-
3 sex related risk factors^{14-17,19}. Nonetheless, in the ESC, NHFA/CSANZ and KHRS
4 guidelines, two differential recommendations are provided about patients with only 1
5 stroke risk factor and for 2 or more stroke risk factors^{14,16,19}. While in the latter
6 (CHA₂DS₂-VASc score ≥ 2) OAC is recommended, with a strong recommendation
7 based on a high level of evidence, the level of evidence regarding the
8 recommendation for patients with CHA₂DS₂-VASc score of 1 is lower, given that
9 fewer such patients were included in the randomised trials.

10

11 In the 2018 ACCP guidelines, the overall recommendation of prescribing all patients
12 with at least 1 stroke risk factor is a stroke recommendation based on moderate
13 quality of evidence¹⁷. Of the most recent guidelines, ACCP and KHRS also underline
14 how, on the basis of some recent evidence, stroke risk assessment needs to be
15 considered a dynamic process and should be reassessed at the regular follow-up
16 visits^{17,19}.

17

18 The Canadian guidelines differ from other guidelines since the evaluation of
19 thromboembolic risk is based on the CHADS-65 algorithm, also known as the CCS
20 algorithm^{13,18}. This algorithm is a three-step evaluation scheme, that recommends
21 evaluating the patient's age first, with all patients aged ≥ 65 years old recommended
22 for OAC, followed by assessment of the presence of stroke risk factors according to
23 the CHADS₂ risk score²³, where patients with at least 1 risk factor should receive
24 OAC, and lastly evaluating the presence of coronary artery disease (CAD) or other
25 arterial vascular disease, recommending the prescription of aspirin in those patients

1 aged <65 years with isolated CAD^{13,18}. The Canadian guidelines remain the only one
2 still recommending the use of aspirin in AF patients aged <65 years with isolated
3 CAD and no other CHADS₂ stroke risk factors. Conversely, all other guidelines firmly
4 recommend against the use of antiplatelet therapy for thromboembolic risk
5 treatment^{14-17,19}.

6
7 When OAC is indicated, all guidelines agree about the preferential use of NOACs
8 over VKA therapy¹³⁻¹⁹, with most giving this a strong recommendation,^{13,14,18,19} All
9 guidelines concurred with the use of VKAs in patients with valvular AF. Where VKAs
10 are used, most guidelines (ESC, APHRS, ACCP, KHRS) recommend to maintain a
11 high quality of OAC control, expressed as time in therapeutic range (TTR) ≥65-
12 70%^{14,15,17,19}.

14 **Evaluation of Bleeding Risk**

15 After the evaluation of thromboembolic risk, all guidelines point the attention to the
16 bleeding risk evaluation (Table 3). Most strongly recommend the use of the HAS-
17 BLED risk score to evaluate bleeding risk, with a moderate to a high quality of
18 evidence^{13,15,17-19}. The ESC guidelines underline how the use of clinical risk scores
19 could be helpful tools in evaluating bleeding risk, but do not recommend one scheme
20 over another¹⁴. Nonetheless, the ESC guidelines underline how, irrespectively of the
21 score used, the main aim is to be to identify those patients with modifiable or
22 potentially modifiable bleeding risk factors¹⁴.

23
24 All guidelines agreed that a high bleeding risk should generally not be considered as
25 a reason to withhold OAC treatment, except those specific situations when the

1 risk/benefit ratio excessively favours no antithrombotic¹³⁻¹⁹. Instead, efforts should
2 be used to identify all the modifiable bleeding risk factors and address them where
3 possible, discussing these with the patient, and providing more frequent and regular
4 checks and follow-up visits¹³⁻¹⁹. Similarly to thromboembolic risk, ACCP and KHRS
5 guidelines recommend a reassessment of bleeding risk on a regular basis in light of
6 its dynamic impact on bleeding risk^{17,19}.

7

8 **Utility of Left Atrial Appendage Closure**

9 All the guidelines agreed that left atrial appendage (LAA) closure should not be
10 routinely used for the management of thromboembolic risk in patients with AF (Table
11 S1). While the Canadian guidelines suggest, with a low quality of evidence, that LAA
12 closure should be considered only as part of the ablation procedure, even though
13 clearly contraindicated in patients at high risk of stroke^{13,18}, other guidelines
14 recommend that LAA closure should only be considered in those patients with
15 absolute contra-indications to OAC use^{14-17,19}. Overall, the guidelines judged the
16 quality of evidence regarding LAA closure to be low.

17

18 **Management of OAC and Antiplatelet Therapy**

19 Several epidemiological studies have shown that AF is often associated with acute
20 coronary syndrome (ACS) and myocardial infarction (MI)²⁴⁻²⁶. One of the main
21 concerns in patients presenting with AF and ACS/MI is the management of dual or
22 triple antithrombotic therapy (OAC plus single or dual antiplatelet therapy) with
23 respect to balancing atherothrombotic, thromboembolic and bleeding risk.

24

1 In the antithrombotic decision-making process, a primary distinction has to be drawn
2 between patients presenting with ACS and those undergoing elective percutaneous
3 coronary intervention (PCI) with stent. For patients presenting with ACS and
4 undergoing urgent PCI with stent, almost all the guidelines recommend treatment
5 with triple antithrombotic, with the duration varying from 1-6 months, with shortening
6 of triple therapy based on bleeding risk¹³⁻¹⁸. For example, the recent ACCP
7 guidelines specifically recommend using triple therapy for 6 months in patients with
8 low bleeding risk, shortening duration to 1 to 3 months in patients with high bleeding
9 risk, while recommending avoiding it completely in those patients with very high
10 bleeding risk¹⁷. Following the period of triple therapy, duration of dual antithrombotic
11 therapy should not be continued longer than 12 months after the PCI. In addition, all
12 guidelines indicate a preference for clopidogrel over aspirin as the choice of
13 antiplatelet drug. Recommendations regarding patients with ACS and undergoing
14 urgent PCI (irrespective of stent placement) are generally on the basis of low or
15 moderate quality of evidence¹³⁻¹⁸.

16
17 Among patients undergoing elective PCI with stent placement, most of the guidelines
18 (ESC, APHRS, NHFA/CSANZ, KHRS) recommend a short duration of triple
19 antithrombotic therapy very short, up to a maximum of 1 month^{14-16,19}. According to
20 ACCP guidelines in patients with low bleeding risk, the duration of triple therapy is
21 recommended for 1 month, followed by 12 months of clopidogrel plus OAC;
22 conversely in patients with high risk of bleeding, while the duration of triple therapy is
23 kept to 1 month, the guidelines recommend shortening the dual antithrombotic
24 therapy up to 6 months after the procedure. Finally, in those patients with very high

1 bleeding risk use of triple therapy is not recommended, and the duration of dual
2 antithrombotic therapy should be kept up to 6 months¹⁷.

3

4 The Canadian guidelines recommend a bit different approach. In the 2016 update
5 they did not recommend at all use of triple therapy for elective PCI, suggesting only
6 dual antithrombotic therapy with clopidogrel. In the 2018 version, they changed the
7 recommendations by introducing the use of triple antithrombotic therapy in elective
8 PCI in consideration of the high risk of thrombotic coronary events associated with
9 some clinical variables (i.e. diabetes mellitus, smoking, chronic kidney disease,
10 previous coronary events, etc.) and of type of stent^{13,18}. Those patients with high risk
11 features are recommended to be treated for up to 6 months with triple antithrombotic
12 therapy, followed by dual therapy for up to 12 months post stent. However, in
13 patients without high risk features, triple therapy is not recommended¹⁸. It is
14 important to underline that all the recommendations regarding the use of triple
15 therapy in AF patients receiving elective PCI are weak and based on moderate to
16 low quality of evidence.

17

18 Regarding OAC prescription, the CCS, APHRS, KHRS guidelines recommend
19 NOACs over VKAs in ACS patients, although there is less robust evidence^{13,15,18,19}.
20 While the NHFA/CSANZ guidelines do not provide any particular recommendation in
21 this regard¹⁶. The ESC guidelines recommend the use of the lowest approved
22 dosage of NOACs when co-administered with antiplatelet drugs¹⁴, while the ACCP
23 guidelines recommend NOACs as equal to VKAs, but with a weaker
24 recommendation based on a lower quality of evidence¹⁷.

25

1 **Management of Oral Anticoagulant in Cardioversion and Ablation Procedures**

2 With regard to ablation procedures, all guidelines agree on three main pillars: i)
3 uninterrupted OAC is recommended for patients undergoing ablation procedure; ii)
4 after procedure, OAC therapy is recommended as compulsory for at least 8 weeks in
5 all the patients; iii) long-term OAC prescription beyond the first 8 weeks, should be
6 based on risk profile and proposed only to patients with high risk of stroke^{14,15,17-19}.

7
8 Regarding the type of OAC to be prescribed for pre- and peri-procedural
9 uninterrupted treatment, the ESC, APhRS and CCS 2018 guidelines all recommend
10 NOACs and VKAs as equal alternatives^{14,15,18}. As a notable exception, the recent
11 ACCP guidelines only recommend dabigatran or rivaroxaban among the NOACs¹⁷.

12
13 With respect to OAC in patients undergoing a cardioversion procedure, all the
14 guidelines agreed on some basic principles: i) in patients with at least 48 hours of
15 proved AF, anticoagulation should be provided for at least 3 weeks to exclude the
16 presence of any left atrial thrombus; ii) as an alternative to OAC, use of a trans-
17 esophageal echocardiogram to exclude the presence of any left atrial thrombus; iii)
18 OAC should be continued for at least 4 weeks after procedure, irrespective of the
19 success of cardioversion procedure¹³⁻¹⁹. Most of the guidelines agree that long-term
20 OAC, irrespective of the success of cardioversion procedure, should be considered
21 on the basis of stroke risk factors¹⁴⁻¹⁹. Several guidelines also explicitly
22 recommended to provide 3 to 4 weeks OAC treatment if a thrombus is identified on
23 the trans-esophageal echocardiogram^{14,15,17,19}. ACCP 2018 and CCS 2018
24 guidelines provided recommendations regarding specific situations. ACCP guidelines
25 provide an indication about not commencing OAC for patients with <48 hours AF and

1 hemodynamic instability, rather initiate parenteral anticoagulation as soon as it is
2 possible¹⁷. In the CCS 2018 guidelines, is indicated that in patients with very short
3 (<12 hours) or short (12-48 hours) AF duration, OAC can be avoided if there is no
4 substantial risk of stroke¹⁸.

5

6 **Management of OAC in Specific Populations**

7 One of the most debated issues in the management of OAC therapy is the
8 prescription in elderly (very elderly) and frail patients (Table S2). Among the
9 guidelines examined, the CCS (having discussed the issue in the previous 2010 and
10 2012 versions, but they do not make any recommendations in 2016 and 2018), and
11 APHS guidelines did not consider this issue^{13,15,18}.

12

13 The ESC guidelines state that the available evidence supports the use of OAC in
14 elderly and frail subjects, due to the high benefit-risk ratio¹⁴. The NHFA/CSANZ
15 guidelines highlight the beneficial effect of OAC in elderly patients observed in
16 observational registries, with a preference for the use of NOACs, due to the high
17 prevalence of polypharmacy, although caution is recommended with dose-
18 adjustment related to renal function¹⁶. The ACCP guidelines recommend a specific
19 individual risk assessment prior to OAC prescription while reaffirming that the benefit
20 of OAC prescription generally outweigh the risk of harm from serious bleeding, whilst
21 highlighting a contraindication to OAC prescription is posed for patients with
22 dementia and no caregiver (to administer OAC)¹⁷. Similar recommendations are
23 included in the KHRS guidelines¹⁹. Guidelines including specific recommendations
24 about elderly patients did not rate these recommendations.

25

1 Another important population is are patients with chronic kidney disease. Impaired
2 renal function is an independent risk factor for stroke, major bleeding and major
3 adverse outcomes in patients with AF²⁷, thus these patients need careful
4 management in order to maximize stroke prevention and reduce bleeding risk, and
5 the guidelines differ in their recommendations for managing such patients (Table S2)
6 and the lower limit for which OAC use is no longer recommended. Both Canadian
7 guidelines suggest that OAC should not be routinely prescribed for patients with
8 glomerular filtration rate (GFR) <15 mL/min, but that use of OAC may be appropriate
9 in some patients in whom there is a stronger preference in avoiding stroke despite
10 the uncertain benefit and the associated bleeding risk^{13,18}. Lack of data, with limited
11 evidence about efficacy and safety of OAC in patients with GFR <30 mL/min and
12 <15 mL/min are claimed by APHRS¹⁵, NHFA/CSANZ¹⁶ and ESC guidelines¹⁴.
13 Although the APHRS, ACCP and KHRS guidelines recognise the limited evidence,
14 they suggest that use of VKAs with well-managed quality of anticoagulation therapy
15 could be considered^{15,17,19}.
16
17 In patients with moderate to severe CKD (GFR 15-30 mL/min), treatment strategies
18 differ across guidelines. Both Canadian guidelines recommend OAC prescription on
19 the basis of stroke risk, with warfarin the preferred agent^{13,18}, while the APHRS,
20 ACCP and KHRS guidelines suggest the use of OAC with caution, with the
21 recommendation to reduce NOACs dosages.^{15,17,19} The ESC guidelines also
22 recommend reducing the NOAC dosage, although the reduction is suggested for
23 patients with GRF 25-50 mL/min. The adjustment of NOACs dosage is also
24 suggested by the other guidelines for patients with GFR >30 and up to 50 or 60
25 mL/min, according to guidelines^{13,15,17-19}. It is relevant to note that the majority of the

1 recommendations are weak and based on a low quality of evidence, underlining the
2 need for more solid evidence.

3

4 One emergent issue is that related to the treatment of patients with cardiac
5 implantable electronic devices, without clinical AF, that are found to have atrial high
6 rate episodes (AHREs). While some guidelines did not consider this issue^{15,19}, others
7 suggest that OAC treatment should be considered in those with prolonged AHREs
8 (>24 hours) and a high risk of stroke (CHA₂DS₂-VASc ≥ 2),^{13,16-18} while further data
9 are needed to support the use of OAC in patients with AHREs of shorter duration.
10 However, the ESC guidelines do not advocate OAC treatment for patients with
11 AHREs¹⁴.

12

13 **Use of an Integrated Management in Patients with Atrial Fibrillation**

14 Given the increased risk for adverse outcomes other than stroke, such as myocardial
15 infarction, cardiovascular death and all-cause death,^{9,10,24,25} in AF patients, there is a
16 need for a more integrated and holistic management approach for AF patients, in
17 order to reduce overall cardiovascular risk^{11,12}. Most guidelines advocate the need
18 for an integrated approach (Table S3), for example, in the 2016 ESC guidelines, in
19 order to improve adherence to treatment, quality of life and long-term outcomes^{14,16-}
20 ¹⁹. However, the operationalisation and implementation of integrated care needs to
21 be simple and practical. To address the latter, both the ACCP and KHRS guidelines
22 have suggested that use of the 'Atrial Fibrillation Better Care' (ABC)²⁸ approach as a
23 practical tool to streamline the integrated management of AF patients^{17,19}.

24

25

1 SUMMARY AND DISCUSSION

2 In this narrative review, we have discussed the main recommendations regarding
3 OAC management for AF patients from contemporary international guidelines. Most
4 guidelines were compiled with a systematic and well-established approach and rated
5 according to a rigorous evaluation system. There was general agreement in the
6 definition of valvular and non-valvular AF, although some heterogeneity was evident
7 in the temporal classification of AF. Despite not being considered in the OAC
8 decision-making process, the type of AF can influence the risk of major adverse
9 outcomes²⁹. Further, the classification of clinical AF influences rate/rhythm
10 management and lack of concordance between the guidelines can be misleading in
11 the evaluation of patients and differing management strategies between physicians.
12
13 Evaluation of thromboembolic risk at baseline is very similar across all the guidelines
14 with most adopting the CHA₂DS₂-VASc score, with the notable exception of
15 Canadian guidelines. The almost universal adoption of CHA₂DS₂-VASc score
16 reflects the strength of the current data supporting its' use a clinical risk score that
17 provides a balance between evidence, practicality and precision³⁰. A recent
18 comparative effectiveness review about the ability of the scores to predict
19 thromboembolic and bleeding events reported that CHADS₂, CHA₂DS₂-VASc and
20 the recent ABC-Stroke³¹ scores were best and had a similar predictive capacity for
21 stroke occurrence³². Nonetheless, CHA₂DS₂-VASc differs from other scores for its
22 capacity to effectively identify those patients with very low risk and does not require
23 expensive and time-consuming laboratory tests to be undertaken compared to the
24 ABC-Stroke score³⁰. Furthermore, recently a systematic review and meta-regression
25 demonstrated that CHA₂DS₂-VASc score represents the score with the highest

1 probability to perform best in predicting the occurrence of all-cause death in AF
2 patients³³.

3

4 The role of the female sex as an independent risk factor, in relation to stroke risk is
5 addressed by all the seven guidelines examined (Table 2)¹³⁻¹⁹. The increased stroke
6 risk in female AF patients has been long discussed^{34,35}. A comprehensive meta-
7 analysis including almost 1 million AF patients demonstrated that female patients
8 with AF were at increased risk of stroke, with a 24% of relative risk increase³⁶.

9 However, a significant relationship was found between increasing age and a
10 progressively higher risk of stroke in female AF patients³⁶. Compelling data from the
11 Danish registries demonstrated that while there were no profound differences
12 between 'low risk' male and female AF patients with no additional stroke risk factors,
13 a sex difference in stroke risk increased with the increasing number of risk factors,
14 suggesting that female sex was "risk modifier" rather than a risk factor per se³⁷.
15 Ignoring the female sex criterion would *underestimate* stroke risk in female patients
16 with ≥ 1 additional stroke risk factor(s), an important consideration when discussing
17 risks with AF patients.

18

19 The second pivotal step on which all the guidelines agree is the evaluation of
20 baseline bleeding risk. While five out of 7 of the guidelines examined adopted HAS-
21 BLED as the clinical risk score to evaluate bleeding risk^{13,15,17-19}, the ESC and
22 NHFA/CSANZ guidelines recognize the utility of the clinical scores to evaluate
23 bleeding risk, but do not recommend the use of any particular score^{14,16}. Conversely,
24 these guidelines adopt an approach based on the identification of modifiable and
25 potentially modifiable bleeding risk factors,^{14,16} despite evidence demonstrating the

1 superiority of HAS-BLED to ORBIT, ATRIA Bleeding, HEMORR₂HAGES scores^{38,39}
2 and to the most recent ABC-Bleeding and GARFIELD-AF Bleeding scores.^{40,41}
3 Furthermore, when compared to an approach based exclusively on modifiable
4 bleeding risk factors as promoted by the ESC guidelines, using the HAS-BLED score
5 was a superior strategy for bleeding risk assessment^{42,43}.

6
7 Regarding the prescription of OAC, the Canadian guidelines still recommend
8 prescribing antiplatelet drugs in patients aged <65 years with isolated CAD and no
9 other stroke risk factors^{13,18}, but all other guidelines support the prescription of OAC
10 in patients with at least one stroke risk factor not related to gender. All the
11 recommendations regarding OAC prescription are strong recommendations and
12 hence supported by solid evidence. Similarly, as largely supported by Phase III
13 randomized clinical trials² and observational studies⁴⁴⁻⁴⁶, all the guidelines
14 recommend the use of NOACs in preference to VKAs. Notwithstanding that globally
15 VKAs are still widely used as OAC, the use of the SAME-TT₂R₂ score is mentioned
16 in some guidelines related to where VKAs are used to help assess the likelihood of
17 patients to achieve an optimal anticoagulation control when prescribed with VKAs,
18 that could guide more intense INR monitoring or the alternative prescription of VKAs
19 and NOACs⁴⁷.

20
21 On the basis of the guideline recommendations and evidence presented, and given
22 that the default should be to offer stroke prevention unless the patient is 'low risk',
23 the so-called 'Birmingham 3-Step' management strategy has been advocated [Figure
24 2]¹. In the first step, AF patients who are low risk are identified through CHA₂DS₂-
25 VASc score, and no antithrombotic therapy is recommended. In the second step,

1 OAC therapy is considered in all AF patients with at least 1 additional non-sex stroke
2 risk factor(s) and risk of bleeding is assessed, to identify those patients at high risk of
3 bleeding (HAS-BLED ≥ 3), to address modifiable bleeding risk factors and plan more
4 frequent follow-up checks. In the third step, treatment with OAC should be started
5 with NOACs as the preferred option – and if a VKA is considered, the SAME-TT₂R₂
6 score can help to identify those patients that would more likely obtain a low TTR
7 (SAME-TT₂R₂ > 2) who can be identified for more regular INR monitoring,
8 education/counselling or to reconsider being prescribed a NOAC.

9
10 Regarding the concomitant use of OAC and antiplatelet drugs, the guidelines
11 examined agree on similar basis. It is recognized that the use of triple antithrombotic
12 therapy in AF with ACS should be based on the balance between
13 atherothrombotic/thromboembolic risk and bleeding risk and that such strategy
14 should be kept as short as possible.

15
16 Use of triple antithrombotic therapy has been traditionally associated to an increased
17 risk of bleeding, with several studies reporting an increased rate of major bleeding
18 events with no relative benefit in terms of thromboembolic and atherosclerotic
19 events)^{48,49}. For example, the WOEST trial reported that a strategy of clopidogrel
20 plus OAC compared to triple antithrombotic therapy was associated with a lower risk
21 of major bleeding with no difference in terms of efficacy⁴⁸. Nevertheless, if good
22 quality anticoagulation control is attained, the risk of major bleeding in such patients
23 undergoing PCI and stent seems to be significantly reduced⁴⁹. The 2018 joint
24 European consensus document underlined the need to shorten triple antithrombotic
25 therapy in AF patients as much as possible, related to clinical presentation, bleeding

1 risk, etc⁵⁰. In this situation, a strategy based on NOACs was associated with a
2 reduced risk of major bleeding events^{51,52}. However, a network meta-analysis
3 concluded that the best treatment strategy for these high-risk patients still appears to
4 be the use of a VKA and single antiplatelet drugs when considering both efficacy and
5 safety, even though the use of low-dose rivaroxaban appears as a valid alternative⁵³.
6 Nevertheless, this network meta-analysis did not include data from the RE-DUAL
7 PCI trial⁵². Future results from other ongoing trials (AUGUSTUS ClinicalTrials.Gov:
8 NCT02415400; ENTRUST-AF-PCI ClinicalTrials.Gov: NCT02866175) will provide
9 further evidence.

10

11 In the clinical scenarios of catheter ablation and cardioversion procedures, the
12 guidelines reviewed shared similar approaches regarding the use of OAC and
13 NOACs. Several studies have examined the use of uninterrupted NOACs in the
14 catheter ablation setting and all data support better safety profile compared to VKAs,
15 with no differences in terms of efficacy^{54,55}. In the cardioversion setting NOACs were
16 similar to VKAs in terms of both efficacy and safety⁵⁶.

17

18 With regard to specific populations (patients with chronic kidney disease, the elderly
19 and frail, patients with AHREs), the guidelines highlight the absence of specific
20 controlled studies exploring the efficacy and safety of OAC and NOACs in these
21 populations. Even though observational data are available and subgroups analysis
22 provided some evidence to draft some recommendations, this evidence was not
23 considered solid enough to provide strong recommendations. Future studies are still
24 needed in patients with chronic kidney disease and those elderly and frail to better
25 substantiate current clinical practice. Regarding patients with AHREs, some studies

1 are currently in progress and will elucidate the risk-benefit ratio of treating these
2 patients with OAC^{57,58}.

3

4 In some of the contemporary guidelines, the need for integrated management for AF
5 patients is highlighted. On the basis of the evidence that AF patients are burdened
6 with an increased risk of major adverse outcomes beyond their mere
7 thromboembolic risks^{9,10,24,25}, an approach that would account for the multiple issues
8 related to the clinical management of these patients is needed^{11,12}. The 2016 ESC
9 guidelines refer to the 'domains of AF management' and the need for a
10 multidisciplinary approach to AF management (with so-called 'Heart Team') but the
11 operationalisation of such an approach requires simple and practical approaches for
12 the AF patient management pathway.

13

14 Indeed, the use of an integrated management approach to AF is associated with a
15 reduced risk of all-cause death, cardiovascular death and rehospitalization^{59,60 61}.

16 Compliance with the ABC pathway is also associated with reduced healthcare
17 costs⁶². As recently highlighted by some guidelines^{17,19}, the ABC pathway has been
18 proposed to streamline an integrated and holistic management approach for patients
19 with AF [Figure 3]²⁸.

20

21 Significant differences are evident between the various guidelines examined for
22 some key issues. For example, the CCS guidelines in not indicating the use of OAC
23 in patients <65 years with isolated CAD^{13,18} represent one example. This notable
24 exception have been firstly reported in the CCS guidelines in the 2012 update⁶³ and
25 it stands on the assumption that CAD implies a low risk of stroke in AF patients

1 (<1.5% per year)⁶³. Several data exist show that in AF patients, the presence of
2 vascular disease and CAD are associated to a significant independent increase in
3 stroke risk⁶⁴⁻⁶⁶.

4
5 Even more differences are related to those issues for which a lower quality of
6 evidence and strength of recommendations is available. These reflect the lack of
7 high-quality data obtained from randomized controlled trials and underline the need
8 for future well-designed and adequately powered studies.

9
10 The use of an approach based on expert consensus review of the published
11 evidence for the APHS and KHRS guidelines^{15,19} could impact on the daily clinical
12 decision-making process, but when a high quality of evidence is available these
13 guidelines are still able to provide solid recommendations. For all the other aspects
14 for which there is a significant degree of uncertainty, there may be a less objective
15 evaluation of the limited scientific evidence available. In any case, many guidelines
16 that use systematic reviews still include many recommendations with Level of
17 Evidence C, which represents expert consensus anyway.

18 19 **CONCLUSION**

20 In this narrative review of contemporary guidelines, there is general agreement on
21 the baseline evaluation of thromboembolic and bleeding risk, as well as a preference
22 for the use of NOACs. More data are still needed to better substantiate
23 recommendations for specific AF subpopulations. The need for an integrated
24 approach and holistic management is highlighted in the more recently published
25 guidelines.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22

FUNDING

No funding was used to prepare this paper.

DISCLOSURE OF INTERESTS

MP reports consulting activity for Boehringer Ingelheim; DAL reports investigator-initiated educational grants from Bristol-Myers Squibb and Boehringer Ingelheim; speaker activity for Boehringer Ingelheim, Bayer and Bristol-Myers Squibb /Pfizer; consultant activity for Bristol-Myers Squibb, Bayer, Boehringer Ingelheim and Daiichi-Sankyo; She is a member of the ACCP 2018 writing committee; GB has received small speaker's fee from Medtronic, Boston, Boehringer and Bayer, outside the submitted work; He is a member of the ACCP 2018 writing committee; GYHL has served as consultant for Bayer/Janssen, BMS/Pfizer, Medtronic, Boehringer Ingelheim, Novartis, Verseon and Daiichi-Sankyo; and speaker for Bayer, BMS/Pfizer, Medtronic, Boehringer Ingelheim, and Daiichi-Sankyo. He is member and chair of the ACCP 2018 writing committee. No fees are received personally.

1 REFERENCES

- 2 1. Lip G, Freedman B, De Caterina R, Potpara TS. Stroke prevention in atrial
3 fibrillation: Past, present and future. Comparing the guidelines and practical
4 decision-making. *Thromb. Haemost.* 2017;117(7):1230-1239.
5 doi:10.1160/TH16-11-0876.
- 6 2. Ruff CT, Giugliano RP, Braunwald E, et al. Comparison of the efficacy and
7 safety of new oral anticoagulants with warfarin in patients with atrial fibrillation:
8 a meta-analysis of randomised trials. *Lancet* 2013. doi:10.1016/S0140-
9 6736(13)62343-0.
- 10 3. Gadsbøll K, Staerk L, Loldrup Fosbøl E, et al. Increased use of oral
11 anticoagulants in patients with atrial fibrillation: temporal trends from 2005 to
12 2015 in Denmark. *Eur. Heart J.* 2017;38(12):899-906.
13 doi:10.1093/eurheartj/ehw658.
- 14 4. Marzec LN, Wang J, Shah ND, et al. Influence of Direct Oral Anticoagulants on
15 Rates of Oral Anticoagulation for Atrial Fibrillation. *J. Am. Coll. Cardiol.*
16 2017;69(20):2475-2484. doi:10.1016/j.jacc.2017.03.540.
- 17 5. Camm AJ, Accetta G, Ambrosio G, et al. Evolving antithrombotic treatment
18 patterns for patients with newly diagnosed atrial fibrillation. *Heart*
19 2017;103(4):307-314. doi:10.1136/heartjnl-2016-309832.
- 20 6. Boriani G, Proietti M, Laroche C, et al. Contemporary stroke prevention
21 strategies in 11 096 European patients with atrial fibrillation: a report from the
22 EURObservational Research Programme on Atrial Fibrillation (EORP-AF)
23 Long-Term General Registry. *Europace* 2017;(November):1-11.
24 doi:10.1093/europace/eux301.
- 25 7. Marijon E, Le Heuzey J-Y, Connolly S, et al. Causes of death and influencing

- 1 factors in patients with atrial fibrillation: a competing-risk analysis from the
2 randomized evaluation of long-term anticoagulant therapy study. *Circulation*
3 2013;128(20):2192-2201. doi:10.1161/CIRCULATIONAHA.112.000491.
- 4 8. Fauchier L, Villejoubert O, Clementy N, et al. Causes of Death and Influencing
5 Factors in Patients with Atrial Fibrillation. *Am. J. Med.* 2016.
6 doi:10.1016/j.amjmed.2016.06.045.
- 7 9. Proietti M, Laroche C, Opolski G, et al. "Real-world" atrial fibrillation
8 management in Europe: observations from the 2-year follow-up of the
9 EURObservational Research Programme-Atrial Fibrillation General Registry
10 Pilot Phase. *Europace* 2017;19(5):722-733. doi:10.1093/europace/euw112.
- 11 10. Proietti M, Laroche C, Nieuwlaat R, et al. Increased burden of comorbidities
12 and risk of cardiovascular death in atrial fibrillation patients in Europe over ten
13 years: A comparison between EORP-AF pilot and EHS-AF registries. *Eur. J.*
14 *Intern. Med.* 2018. doi:10.1016/j.ejim.2018.05.016.
- 15 11. Kotecha D, Breithardt G, Camm AJ, et al. Integrating new approaches to atrial
16 fibrillation management: The 6th AFNET/EHRA Consensus Conference.
17 *Europace* 2018;20(3):395-407. doi:10.1093/europace/eux318.
- 18 12. Kirchhof P. The future of atrial fibrillation management: integrated care and
19 stratified therapy. *Lancet (London, England)* 2017;390(10105):1873-1887.
20 doi:10.1016/S0140-6736(17)31072-3.
- 21 13. Macle L, Cairns J, Leblanc K, et al. 2016 Focused Update of the Canadian
22 Cardiovascular Society Guidelines for the Management of Atrial Fibrillation.
23 *Can. J. Cardiol.* 2016. doi:10.1016/j.cjca.2016.07.591.
- 24 14. Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC Guidelines for the
25 management of atrial fibrillation developed in collaboration with EACTS. *Eur.*

- 1 *Heart J.* 2016;37(38):2893-2962. doi:10.1093/eurheartj/ehw210.
- 2 15. Chiang C-E, Okumura K, Zhang S, et al. 2017 consensus of the Asia Pacific
3 Heart Rhythm Society on stroke prevention in atrial fibrillation. *J. Arrhythmia*
4 2017;33(4):345-367. doi:10.1016/j.joa.2017.05.004.
- 5 16. NHFA CSANZ Atrial Fibrillation Guideline Working Group D, Brieger D,
6 Amerena J, et al. National Heart Foundation of Australia and the Cardiac
7 Society of Australia and New Zealand: Australian Clinical Guidelines for the
8 Diagnosis and Management of Atrial Fibrillation 2018. *Heart. Lung Circ.*
9 2018;27(10):1209-1266. doi:10.1016/j.hlc.2018.06.1043.
- 10 17. Lip GYH, Banerjee A, Boriani G, et al. Antithrombotic Therapy for Atrial
11 Fibrillation: CHEST Guideline and Expert Panel Report. *Chest*
12 2018;154(5):1121-1201. doi:10.1016/j.chest.2018.07.040.
- 13 18. Andrade JG, Verma A, Mitchell LB, et al. 2018 Focused Update of the
14 Canadian Cardiovascular Society Guidelines for the Management of Atrial
15 Fibrillation. *Can. J. Cardiol.* 2018;34(11):1371-1392.
16 doi:10.1016/j.cjca.2018.08.026.
- 17 19. Joung B, Lee JM, Lee KH, et al. 2018 Korean Guideline of Atrial Fibrillation
18 Management. *Korean Circ. J.* 2018;48(12):1033. doi:10.4070/kcj.2018.0339.
- 19 20. Gillis AM, Skanes AC, Committee CCSAFG. Canadian Cardiovascular Society
20 atrial fibrillation guidelines 2010: implementing GRADE and achieving
21 consensus. *Can J Cardiol* 2011;27(1):27-30. doi:10.1016/j.cjca.2010.11.003.
- 22 21. Camm AJ, Kirchhof P, Lip GYH, et al. Guidelines for the management of atrial
23 fibrillation. *Eur. Heart J.* 2010;31(19):2369-2429.
24 doi:10.1093/eurheartj/ehq278.
- 25 22. Camm A, Lip G, De Caterina R, et al. 2012 focused update of the ESC

- 1 Guidelines for the management of atrial fibrillation: an update of the 2010 ESC
2 Guidelines for the management of atrial fibrillation. Developed with the special
3 contribution of the European Heart Rhythm Association. *Eur Hear. J*
4 2012;33:2719-2747.
- 5 23. Gage BF, Waterman AD, Shannon W, Boehler M, Rich MW, Radford MJ.
6 Validation of clinical classification schemes for predicting stroke: results from
7 the National Registry of Atrial Fibrillation. *JAMA* 2001;285(22):2864-70.
8 Available at: <http://www.ncbi.nlm.nih.gov/pubmed/11401607>. Accessed
9 November 3, 2014.
- 10 24. Soliman EZ, Safford MM, Muntner P, et al. Atrial fibrillation and the risk of
11 myocardial infarction. *JAMA Intern. Med.* 2014;174(1):107-14.
12 doi:10.1001/jamainternmed.2013.11912.
- 13 25. Soliman EZ, Lopez F, O'Neal WT, et al. Atrial Fibrillation and Risk of ST-
14 Segment-Elevation Versus Non-ST-Segment-Elevation Myocardial Infarction:
15 The Atherosclerosis Risk in Communities (ARIC) Study. *Circulation*
16 2015;131(21):1843-50. doi:10.1161/CIRCULATIONAHA.114.014145.
- 17 26. Violi F, Davì G, Proietti M, et al. Ankle-Brachial Index and cardiovascular
18 events in atrial fibrillation: The ARAPACIS study. *Thromb. Haemost.*
19 2016;115(4). doi:10.1160/TH15-07-0612.
- 20 27. Lau YC, Proietti M, Guiducci E, Blann AD, Lip GYH. Atrial Fibrillation and
21 Thromboembolism in Patients With Chronic Kidney Disease. *J. Am. Coll.*
22 *Cardiol.* 2016;68(13). doi:10.1016/j.jacc.2016.06.057.
- 23 28. Lip GYH. The ABC pathway: an integrated approach to improve AF
24 management. *Nat. Rev. Cardiol.* 2017;14(11):627-628.
25 doi:10.1038/nrcardio.2017.153.

- 1 29. Ganesan AN, Chew DP, Hartshorne T, et al. The impact of atrial fibrillation
2 type on the risk of thromboembolism, mortality, and bleeding: a systematic
3 review and meta-analysis. *Eur. Heart J.* 2016;37(20):1591-1602.
4 doi:10.1093/eurheartj/ehw007.
- 5 30. Proietti M, Mujovic N, Potpara TS. Optimizing Stroke and Bleeding Risk
6 Assessment in Patients with Atrial Fibrillation: A Balance of Evidence,
7 Practicality and Precision. *Thromb. Haemost.* 2018;118(12):2014-2017.
8 doi:10.1055/s-0038-1676074.
- 9 31. Oldgren J, Hijazi Z, Lindbäck J, et al. Performance and Validation of a Novel
10 Biomarker-Based Stroke Risk Score for Atrial Fibrillation Clinical Perspective.
11 *Circulation* 2016;134(22):1697-1707.
12 doi:10.1161/CIRCULATIONAHA.116.022802.
- 13 32. Borre ED, Goode A, Raitz G, et al. Predicting Thromboembolic and Bleeding
14 Event Risk in Patients with Non-Valvular Atrial Fibrillation: A Systematic
15 Review. *Thromb. Haemost.* 2018;118(12):2171-2187. doi:10.1055/s-0038-
16 1675400.
- 17 33. Proietti M, Farcomeni A, Romiti GF, et al. Association between clinical risk
18 scores and mortality in atrial fibrillation: Systematic review and network meta-
19 regression of 669,000 patients. *Eur. J. Prev. Cardiol.* 2018:204748731881766.
20 doi:10.1177/2047487318817662.
- 21 34. Lane DA, Lip GYH. Female gender is a risk factor for stroke and
22 thromboembolism in atrial fibrillation patients. *Thromb. Haemost.*
23 2009;101(5):802-5.
- 24 35. Poli D, Antonucci E. Epidemiology, diagnosis, and management of atrial
25 fibrillation in women. *Int. J. Womens. Health* 2015;7:605-14.

- 1 doi:10.2147/IJWH.S45925.
- 2 36. Marzona I, Proietti M, Farcomeni A, et al. Sex differences in stroke and major
3 adverse clinical events in patients with atrial fibrillation: A systematic review
4 and meta-analysis of 993,600 patients. *Int. J. Cardiol.* 2018.
5 doi:10.1016/j.ijcard.2018.07.044.
- 6 37. Nielsen PB, Skjøth F, Overvad TF, Larsen TB, Lip GYH. Female Sex Is a Risk
7 Modifier Rather Than a Risk Factor for Stroke in Atrial Fibrillation: Should We
8 Use a CHA2DS2-VA Score Rather Than CHA2DS2-VASc? *Circulation*
9 2018;137(8):832-840. doi:10.1161/CIRCULATIONAHA.117.029081.
- 10 38. Senoo K, Proietti M, Lane DA, Lip GYH. Evaluation of the HAS-BLED, ATRIA
11 and ORBIT bleeding risk scores in atrial fibrillation patients on warfarin. *Am. J.*
12 *Med.* 2015. doi:10.1016/j.amjmed.2015.10.001.
- 13 39. Proietti M, Senoo K, Lane DA, Lip GYH. Major Bleeding in Patients with Non-
14 Valvular Atrial Fibrillation: Impact of Time in Therapeutic Range on
15 Contemporary Bleeding Risk Scores. *Sci. Rep.* 2016;6:24376.
16 doi:10.1038/srep24376.
- 17 40. Esteve-Pastor MA, Rivera-Caravaca JM, Roldan V, et al. Long-term bleeding
18 risk prediction in “real world” patients with atrial fibrillation: Comparison of the
19 HAS-BLED and ABC-Bleeding risk scores. The Murcia Atrial Fibrillation
20 Project. *Thromb Haemost* 2017;117(10):1848-1858. doi:10.1160/th17-07-
21 0478.
- 22 41. Proietti M, Rivera-Caravaca JM, Esteve-Pastor MA, Romiti GF, Marin F, Lip
23 GYH. Predicting Bleeding Events in Anticoagulated Patients With Atrial
24 Fibrillation: A Comparison Between the HAS-BLED and GARFIELD-AF
25 Bleeding Scores. *J. Am. Heart Assoc.* 2018;7(18).

- 1 doi:10.1161/JAHA.118.009766.
- 2 42. Chao T-F, Lip GYH, Lin Y-J, et al. Incident Risk Factors and Major Bleeding in
3 Patients with Atrial Fibrillation Treated with Oral Anticoagulants: A Comparison
4 of Baseline, Follow-up and Delta HAS-BLED Scores with an Approach
5 Focused on Modifiable Bleeding Risk Factors. *Thromb. Haemost.*
6 2018;118(4):768-777. doi:10.1055/s-0038-1636534.
- 7 43. Esteve-Pastor MA, Rivera-Caravaca JM, Shantsila A, Roldán V, Lip GYH,
8 Marín F. Assessing Bleeding Risk in Atrial Fibrillation Patients: Comparing a
9 Bleeding Risk Score Based Only on Modifiable Bleeding Risk Factors against
10 the HAS-BLED Score. The AMADEUS Trial. *Thromb. Haemost.*
11 2017;117(12):2261-2266. doi:10.1160/TH17-10-0710.
- 12 44. Carmo J, Moscoso Costa F, Ferreira J, Mendes M. Dabigatran in real-world
13 atrial fibrillation. Meta-analysis of observational comparison studies with
14 vitamin K antagonists. *Thromb. Haemost.* 2016;116(4):754-763.
15 doi:10.1160/TH16-03-0203.
- 16 45. Bai Y, Deng H, Shantsila A, Lip GYH. Rivaroxaban Versus Dabigatran or
17 Warfarin in Real-World Studies of Stroke Prevention in Atrial Fibrillation.
18 *Stroke* 2017;48(4):970-976. doi:10.1161/STROKEAHA.116.016275.
- 19 46. Proietti M, Romanazzi I, Romiti GF, Farcomeni A, Lip GYH. Real-world use of
20 apixaban for stroke prevention in atrial fibrillation: A systematic review and
21 meta-analysis. *Stroke* 2018;49(1):98-106.
22 doi:10.1161/STROKEAHA.117.018395.
- 23 47. Zulkifly H, Lip GYH, Lane DA. Use of the SAME-TT 2 R 2 score to predict
24 anticoagulation control in atrial fibrillation and venous thromboembolism
25 patients receiving vitamin K antagonists: A review. *Hear. Rhythm*

- 1 2018;15(4):615-623. doi:10.1016/j.hrthm.2017.11.026.
- 2 48. Dewilde WJM, Oirbans T, Verheugt FWA, et al. Use of clopidogrel with or
3 without aspirin in patients taking oral anticoagulant therapy and undergoing
4 percutaneous coronary intervention: an open-label, randomised, controlled
5 trial. *Lancet* 2013;381(9872):1107-1115. doi:10.1016/S0140-6736(12)62177-1.
- 6 49. Proietti M, Airaksinen KEJJ, Rubboli A, et al. Time in therapeutic range and
7 major adverse outcomes in atrial fibrillation patients undergoing percutaneous
8 coronary intervention: The Atrial Fibrillation Undergoing Coronary Artery
9 Stenting (AFCAS) registry. *Am. Heart J.* 2017;190:86-93.
10 doi:10.1016/j.ahj.2017.05.016.
- 11 50. Lip GYH, Collet J-P, Haude M, et al. 2018 Joint European consensus
12 document on the management of antithrombotic therapy in atrial fibrillation
13 patients presenting with acute coronary syndrome and/or undergoing
14 percutaneous cardiovascular interventions: a joint consensus document of the
15 Europ. *Europace* 2018. doi:10.1093/europace/euy174.
- 16 51. Gibson CM, Mehran R, Bode C, et al. Prevention of Bleeding in Patients with
17 Atrial Fibrillation Undergoing PCI. *N. Engl. J. Med.* 2016;375(25):2423-2434.
18 doi:10.1056/NEJMoa1611594.
- 19 52. Cannon CP, Bhatt DL, Oldgren J, et al. Dual Antithrombotic Therapy with
20 Dabigatran after PCI in Atrial Fibrillation. *N. Engl. J. Med.*
21 2017;NEJMoa1708454. doi:10.1056/NEJMoa1708454.
- 22 53. Gong X, Tang S, Li J, Zhang X, Tian X, Ma S. Antithrombotic therapy
23 strategies for atrial fibrillation patients undergoing percutaneous coronary
24 intervention: A systematic review and network meta-analysis. Pizzi C, ed.
25 *PLoS One* 2017;12(10):e0186449. doi:10.1371/journal.pone.0186449.

- 1 54. Ge Z, Faggioni M, Baber U, et al. Safety and efficacy of nonvitamin K
2 antagonist oral anticoagulants during catheter ablation of atrial fibrillation: A
3 systematic review and meta-analysis. *Cardiovasc. Ther.* 2018;36(5):e12457.
4 doi:10.1111/1755-5922.12457.
- 5 55. Zhao Y, Lu Y, Qin Y. A meta-analysis of randomized controlled trials of
6 uninterrupted periprocedural anticoagulation strategy in patients undergoing
7 atrial fibrillation catheter ablation. *Int. J. Cardiol.* 2018;270:167-171.
8 doi:10.1016/j.ijcard.2018.06.024.
- 9 56. Brunetti ND, Tarantino N, De Gennaro L, Correale M, Santoro F, Di Biase M.
10 Direct oral anti-coagulants compared to vitamin-K antagonists in cardioversion
11 of atrial fibrillation: an updated meta-analysis. *J. Thromb. Thrombolysis*
12 2018;45(4):550-556. doi:10.1007/s11239-018-1622-5.
- 13 57. Lopes RD, Alings M, Connolly SJ, et al. Rationale and design of the Apixaban
14 for the Reduction of Thrombo-Embolism in Patients With Device-Detected
15 Sub-Clinical Atrial Fibrillation (ARTESiA) trial. *Am. Heart J.* 2017;189:137-145.
16 doi:10.1016/j.ahj.2017.04.008.
- 17 58. Kirchhof P, Blank BF, Calvert M, et al. Probing oral anticoagulation in patients
18 with atrial high rate episodes: Rationale and design of the Non-vitamin K
19 antagonist Oral anticoagulants in patients with Atrial High rate episodes
20 (NOAH-AFNET 6) trial. *Am. Heart J.* 2017;190:12-18.
21 doi:10.1016/j.ahj.2017.04.015.
- 22 59. Gallagher C, Elliott AD, Wong CX, et al. Integrated care in atrial fibrillation: A
23 systematic review and meta-analysis. *Heart* 2017;103(24):1947-1953.
24 doi:10.1136/heartjnl-2016-310952.
- 25 60. Proietti M, Romiti GF, Olshansky B, Lane DA, Lip GYH. Improved Outcomes

- 1 by Integrated Care of Anticoagulated Patients with Atrial Fibrillation Using the
2 Simple ABC (Atrial Fibrillation Better Care) Pathway. *Am. J. Med.* 2018.
3 doi:10.1016/j.amjmed.2018.06.012.
- 4 61. Pastori D, Pignatelli P, Menichelli D, Violi F, Lip GYH. Integrated Care
5 Management of Patients With Atrial Fibrillation and Risk of Cardiovascular
6 Events. *Mayo Clin. Proc.* 2018. doi:10.1016/j.mayocp.2018.10.022.
- 7 62. Pastori D, Farcomeni A, Pignatelli P, Violi F, Lip GY. ABC (Atrial fibrillation
8 Better Care) pathway and healthcare costs in atrial fibrillation. The ATHERO-
9 AF study. *Am. J. Med.* 2019;0(0). doi:10.1016/j.amjmed.2019.01.003.
- 10 63. Skanes AC, Healey JS, Cairns JA, et al. Focused 2012 update of the
11 Canadian Cardiovascular Society atrial fibrillation guidelines:
12 recommendations for stroke prevention and rate/rhythm control. *Can. J.*
13 *Cardiol.* 2012;28(2):125-36. doi:10.1016/j.cjca.2012.01.021.
- 14 64. Anandasundaram B, Lane DA, Apostolakis S, Lip GYH. The impact of
15 atherosclerotic vascular disease in predicting a stroke, thromboembolism and
16 mortality in atrial fibrillation patients: a systematic review. *J. Thromb. Haemost.*
17 2013;11(5):975-87. doi:10.1111/jth.12177.
- 18 65. Steensig K, Olesen KKW, Thim T, et al. Coronary artery disease is
19 independent risk factor for stroke among patients with atrial fibrillation. *J. Am.*
20 *Coll. Cardiol.* 2018. doi:10.1016/j.jacc.2018.08.1046.
- 21 66. Steensig K, Olesen KKW, Thim T, et al. Should the Presence or Extent of
22 Coronary Artery Disease be Quantified in the CHA2DS2-VASc Score in Atrial
23 Fibrillation? A Report from the Western Denmark Heart Registry. *Thromb.*
24 *Haemost.* 2018;118(12):2162-2170. doi:10.1055/s-0038-1675401.

25

ACCEPTED MANUSCRIPT

1 **FIGURE LEGENDS**

2

3 **Figure 1: Proportion of Papers Related to Atrial Fibrillation in PubMed from**

4 **Inception to 2017**

5 Legend: AF= Atrial Fibrillation

6

7 **Figure 2: The 'Birmingham 3-Step' Management Strategy for Anticoagulation in**

8 **Patients with Atrial Fibrillation**

9 Legend: NOAC= Non-vitamin K Antagonist Oral Anticoagulant; OAC= Oral

10 Anticoagulant; TTR= Time in Therapeutic Range; VKA= Vitamin K Antagonist.

11

12 **Figure 3: Atrial Fibrillation Better Care (ABC) Pathway for Integrated Care in**

13 **Atrial Fibrillation Patients**

1 **Table 1:** Summary of General Characteristics and Definitions of Contemporary Atrial Fibrillation Guidelines

	CCS	ESC	APHRS
Year	2016	2016	2017
Primary Source	CJC 2016; 32 (10) ¹³	EHJ 2016; 37 (38) ¹⁴	J Arrhythmia 2017; 33 (4) ¹⁵
Guidelines Methodology	Systematic search according to PICO; GRADE rating of evidence	Systematic search according to PICOT; Experts plenary discussion	Expert Consensus Review
Strength of Recommendations	Strong, Conditional, Weak	Classes I-IIa-IIb-III	Not explicitly assessed
Quality of Evidence	High, Moderate, Low, Very Low	Level A-B-C	Not explicitly assessed
Conflict of Interest Process	Not Reported	Detailed disclosure of all real or potential sources of COI publicly available	Reported in acknowledgment
Classification of AF	New onset, paroxysmal, persistent or permanent	First diagnosed, paroxysmal, persistent, long-standing persistent, permanent	Not explicit
Evaluation of Valvular Origin	Rheumatic mitral stenosis, mitral valve repair, mechanical or bio-prosthetic heart valve	Rheumatic valvular disease (predominantly mitral stenosis) or mechanical heart valves	Not explicitly assessed

2

3

1 **Table 1 (continued):** Summary of General Characteristics and Definitions of Contemporary Atrial Fibrillation Guidelines

	NHFA/CSANZ	ACCP	CCS	KHRS
Year	2018	2018	2018	2018
Primary Source	HLC 2018; 27 (10) ¹⁶	Chest 2018;154 (5) ¹⁷	CJC 2018; 34 (11) ¹⁸	KCJ 2018; 48 (12) ¹⁹
Guidelines Methodology	Systematic search according to Clinical Questions; GRADE rating of evidence	Systematic search according to PICO-guided Clinical Questions; GRADE rating of evidence	Systematic search according to PICO; GRADE rating of evidence	Expert Consensus Review
Strength of Recommendations	Strong, Weak	Strong, Weak	Strong, Conditional, Weak	Classes I-IIa-IIb-III
Quality of Evidence	High, Moderate, Low	High, Moderate, Low, Very Low	High, Moderate, Low, Very Low	Level A-B-C
Conflict of Interest Process	Direct or indirect relationship to any third party, both financial and non-financial	Central COIs review. If manageable potential COI, voting on relevant issues was prohibited	Not Reported	Reported in acknowledgment
Classification of AF	Paroxysmal, persistent, long-standing persistent, permanent	Paroxysmal, persistent, long-standing persistent, permanent	New onset, paroxysmal, persistent or permanent	Not explicit
Evaluation of Valvular Origin	Moderate to severe mitral stenosis or mechanical heart valve	Moderate to severe mitral stenosis or mechanical heart valve	Rheumatic mitral stenosis, moderate-severe nonrheumatic mitral stenosis, or a mechanical heart valve	Not explicitly assessed

1 **Legend:** APHRS= Asia Pacific Heart Rhythm Society; CCS= Canadian Cardiovascular Society; CJC= Canadian Journal of
2 Cardiology; COI= Conflict of Interest; CSANZ= Cardiac Society of Australia and New Zealand; EHJ= European Heart Journal;
3 ESC= European Society of Cardiology; GRADE= Grading of Recommendations, Assessment, Development and Evaluation; HLC=
4 Heart, Lung and Circulation; KCJ= Korean Circulation Journal; NHFA= National Heart Foundation of Australia; PICO(T)=
5 Population, Intervention, Comparison, Outcome, (Time).

6

1 **Table 2:** Baseline Thromboembolic Risk Evaluation and Oral Anticoagulation Prescription Algorithm

	CCS	ESC	APHRS
Year	2016	2016	2017
Thromboembolic Risk Assessment	CHADS ₂ -65 (‘CCS Algorithm’)	CHA ₂ DS ₂ -VASc	CHA ₂ DS ₂ -VASc
Rating of Evidence	Strong Recommendation, High-Quality Evidence	Class I, Level A	Not rated
OAC Prescription Algorithm	i) OAC should be considered for all patients ≥65 years old or with ≥1 CHADS ₂ risk factors. ii) <65 years old and with arterial disease ASA should be considered	i) OAC is indicated in all patients with a CHA ₂ DS ₂ -VASc ≥2, excluding sex category ii) OAC should be considered in all patients with just 1 CHA ₂ DS ₂ -VASc risk factors, excluding sex category	OAC is indicated in all patients with a CHA ₂ DS ₂ -VASc ≥1, excluding sex category
Rating of Evidence	i) Strong Recommendation, Moderate-Quality Evidence ii) Conditional Recommendation, Moderate-Quality Evidence	i) Class I, Level A ii) Class IIa, Level B	Not rated
Use of NOACs	A NOAC is preferred over VKA	A NOAC is preferred over VKA	A NOAC is preferred over VKA
Rating of Evidence	Strong Recommendation, High-Quality Evidence	Class I, Level A	Not rated

2

1 **Table 2 (continued):** Baseline Thromboembolic Risk Evaluation and Oral Anticoagulation Prescription Algorithm

	NHFA/CSANZ	ACCP	CCS	KHRS
Year	2018	2018	2018	2018
Thromboembolic Risk Assessment	CHA ₂ DS ₂ -VA	CHA ₂ DS ₂ -VASc	CHADS ₂ -65 (‘CCS Algorithm’)	CHA ₂ DS ₂ -VASc
Rating of Evidence	Strong Recommendation, Moderate-Quality Evidence	Strong Recommendation, Moderate-Quality Evidence	Strong Recommendation, High-Quality Evidence (2014)	Class I, Level A
OAC Prescription Algorithm	i) OAC is indicated in all patients with CHA ₂ DS ₂ -VA ≥2 ii) OAC should be considered in all patients with CHA ₂ DS ₂ -VA 1	OAC is indicated in all patients with a CHA ₂ DS ₂ -VASc ≥1, excluding sex category	i) OAC should be considered for all patients ≥65 years old or with ≥1 CHADS ₂ risk factors. ii) <65 years old and with arterial disease ASA should be considered	i) OAC is indicated in all patients with a CHA ₂ DS ₂ -VASc ≥2, excluding sex category ii) OAC should be considered in all patients with just 1 CHA ₂ DS ₂ -VASc risk factors, excluding sex category
Rating of Evidence	i) Strong Recommendation, High-Quality Evidence ii) Strong Recommendation, Moderate-Quality Evidence	Strong Recommendation, Moderate-Quality Evidence	i) Strong Recommendation, Moderate-Quality Evidence ii) Conditional Recommendation, Moderate-Quality Evidence (2014)	i) Class I, Level A ii) Class IIa, Level B
Use of NOACs	A NOAC is preferred over VKA	A NOAC is preferred over VKA	A NOAC is preferred over VKA	A NOAC is preferred over VKA
Rating of Evidence	Strong Recommendation, Moderate-Quality Evidence	Strong Recommendation, Moderate-Quality Evidence	Strong Recommendation, High-Quality Evidence (2014)	Class I, Level A

2 **Legend:** ASA= Acetylsalicylic acid; CHADS= Congestive Heart Failure, Hypertension, Age, Diabetes Mellitus, Stroke/Transient

3 Ischemic Attack; CHA₂DS₂-VASc= Congestive Heart Failure, Hypertension, Age≥75 years, Diabetes Mellitus, Stroke/Transient

- 1 Ischemic Attack, Vascular Disease, Age 65-74 years, Sex category; NOAC= Non-vitamin K antagonist oral anticoagulant; OAC=
- 2 Oral anticoagulant; VKA= Vitamin K Antagonist; for other acronyms please see Table 1 legend.
- 3

ACCEPTED MANUSCRIPT

1 **Table 3:** Baseline Bleeding Risk Evaluation and Associated Recommendations

	CCS	ESC	APHRs
Year	2016	2016	2017
Bleeding Risk Assessment	HAS-BLED	Use of clinical risk scores to evaluate modifiable and potentially modifiable risk factors for major bleeding	HAS-BLED
Rating of Evidence	Strong Recommendation, High-Quality Evidence (2010)	Class IIa, Level B	Not rated
Associated Recommendation	Adopt specific measures to mitigate bleeding risk factors	Not withhold OAC. Identify and correct modifiable bleeding risk factors	For patients with HAS-BLED ≥ 3 not withhold OAC and provide regular review and follow-up of the modifiable bleeding risk factors.

2

3

1 **Table 3 (continued):** Baseline Bleeding Risk Evaluation and Associated Recommendations

	NHFA/CSANZ	ACCP	CCS	KHRS
Year	2018	2018	2018	2018
Bleeding Risk Assessment	Identification of reversible bleeding risk factors	HAS-BLED	HAS-BLED	HAS-BLED
Rating of Evidence	Strong Recommendation, Low-Quality of Evidence	Strong Recommendation, Moderate-Quality of Evidence	Strong Recommendation, High-Quality Evidence (2010)	Class I, Level A
Associated Recommendation	Minimisation of bleeding risk through treating of reversible risk factors	HAS-BLED ≥ 3 should not be a reason to withhold OAC. Those patients at higher bleeding risk is warranted for more frequent and regular reviews and follow-up	Adopt specific measures to mitigate bleeding risk factors	A high bleeding risk is not a reason to withhold OAC treatment. Modifiable bleeding risk factors should be addressed to reduce bleeding risk

2 **Legend:** HAS-BLED= Hypertension, Abnormal renal/liver function, Stroke, Bleeding, Labile anticoagulation quality, Elderly, Drugs

3 or alcohol; for other acronyms please see previous tables legends.

4

1 **Table 4:** Combination of OAC with Antiplatelet Drugs in patients with Concomitant Cardiac Disease

	CCS	ESC	APHRS
Year	2016	2016	2017
Patients with ACS	<p>i) In patients <65 years old and no CHADS₂ risk factors 12 months treatment with aspirin and P2Y12 inhibitor (chosen according to risk and implementation of PCI) with indefinite treatment with aspirin if PCI has been performed</p> <p>ii) In patients ≥65 years old and CHADS₂ ≥1 and no PCI is undertaken clopidogrel 75 mg and OAC for 12 months followed by only OAC</p> <p>iii) In patients ≥65 years old and CHADS₂ ≥1 and PCI is undertaken ASA 81 mg + clopidogrel 75 mg + OAC for 3/6 months (according to risk) followed by clopidogrel 75 mg + OAC up to 12 months then OAC</p>	<p>i) In patients not undergoing PCI dual therapy with OAC and aspirin or clopidogrel should be considered up to 12 months</p> <p>ii) In patients undergoing PCI triple therapy with OAC, aspirin and clopidogrel should be considered from 1 to 6 months on the basis of bleeding risk, followed by dual therapy with aspirin or clopidogrel</p> <p>iii) Duration of combination therapy, especially triple therapy, should be kept to the minimum, balancing risk of bleeding and recurrent events</p>	In patients with ACS triple therapy can be continued from 1 to 6 months according to bleeding risk (high or low) with dual therapy up to 12 months after the event
Rating of Evidence	<p>i) Strong Recommendation, High-Quality Evidence</p> <p>ii) Conditional Recommendation, Low-Quality Evidence</p> <p>iii) Conditional Recommendation, Low-Quality Evidence</p>	<p>i) Class IIa, Level C</p> <p>ii) Class IIa, Level C</p> <p>iii) Class IIa, Level B</p>	Not rated
Elective PCI	i) In patients <65 years and no CHADS ₂	i) In patients undergoing elective PCI, use	In patients with elective PCI triple therapy

	<p>risk factors indefinite treatment with aspirin + 12 months of treatment with clopidogrel is recommended</p> <p>ii) In patients ≥ 65 and CHADS₂ risk factors OAC + clopidogrel with no aspirin are indicated for 12 months followed by indefinite OAC</p>	<p>of triple therapy with OAC, aspirin and clopidogrel should be limited to 1 month</p> <p>ii) Dual therapy with OAC and aspirin or clopidogrel, could be continued up to 6 or 12 months according to bleeding risk</p>	<p>should be continued for 1 month, with dual therapy continued up to 6 or 12 months, according to bleeding risk (high or low)</p>
Rating of Evidence	<p>i) Strong Recommendation, High-Quality Evidence</p> <p>ii) Strong Recommendation, High-Quality Evidence</p>	<p>i) Class IIa, Level B</p> <p>ii) Class IIa, Level C</p>	Not rated
Use of NOACs	When OAC indicated a NOAC is preferred over warfarin	When NOAC is used the lowest recommended dose should be administered together with antiplatelet therapy	A NOAC is preferred over warfarin
Rating of Evidence	Not rated	Not rated	Not rated

1

2

1 **Table 4 (continued):** Combination of OAC with Antiplatelet Drugs in patients with Concomitant Cardiac Disease

	NHFA/CSANZ	ACCP	CCS	KHRS
Year	2018	2018	2018	2018
Patients with ACS	<p>i) In patients with ACS or PCI duration of triple therapy should be kept as short as possible to minimize risk of bleeding, still ensuring the coverage of the high risk of recurrent event/stent thrombosis</p> <p>ii) After triple therapy, dual therapy with OAC and aspirin 100 mg or clopidogrel 75 mg is recommended</p>	<p>i) In patients with ACS and low bleeding risk, triple therapy is suggested up to 6 months, followed by OAC plus single antiplatelet (preferably clopidogrel) up to 12 months</p> <p>ii) In patients with ACS and high bleeding risk, triple therapy is suggested from 1 to 3 months, followed by OAC plus antiplatelet (preferably clopidogrel) up to 12 months</p> <p>iii) In patients with very high bleeding risk, a strategy with OAC and single antiplatelet (preferably clopidogrel) for 6-9 months is suggested</p>	<p>i) In patients ≤ 65 years and no CHADS₂, use of antiplatelet therapy according to characteristics and extent of disease as directed by other guidelines</p> <p>ii) In patients ≥ 65 years and CHADS₂ ≥ 1 not undergoing PCI, OAC plus P2Y₁₂ inhibitor (preferably clopidogrel) is indicated for 12 months</p> <p>iii) In patients ≥ 65 years and CHADS₂ ≥ 1 undergoing PCI, OAC, aspirin and clopidogrel are indicated up to 6 months, followed by OAC plus clopidogrel up to 12 months</p>	No recommendation
Rating of Evidence	<p>i) Strong Recommendation, Moderate-Quality of Evidence</p> <p>ii) Strong Recommendation, Low-Quality of Evidence</p>	<p>i) Weak Recommendation, Low-Quality of Evidence</p> <p>ii) Weak Recommendation, Low-Quality of Evidence</p> <p>iii) Weak Recommendation,</p>	<p>i) Not rated</p> <p>ii) Weak Recommendation, Low-Quality of Evidence</p> <p>iii) Weak Recommendation, Moderate-Quality of Evidence</p>	-

		Low-Quality of Evidence		
Elective PCI	<p>i) In patients with ACS or PCI duration of triple therapy should be kept as short as possible to minimize risk of bleeding, still ensuring the coverage of the high risk of recurrent event/stent thrombosis</p> <p>ii) After triple therapy, dual therapy with OAC and aspirin 100 mg or clopidogrel 75 mg is recommended</p>	<p>i) In patients receiving PCI and low bleeding risk, triple therapy is suggested for 1 month, followed by OAC plus single antiplatelet (preferably clopidogrel) up to 12 months</p> <p>ii) In patients receiving PCI and high bleeding risk, triple therapy is suggested for 1 month, followed by OAC plus antiplatelet (preferably clopidogrel) up to 6 months</p> <p>iii) In patients with very high bleeding risk, a strategy with OAC and single antiplatelet (preferably clopidogrel) for 6 months is suggested</p>	<p>i) In patients ≥ 65 years and CHADS₂ ≥ 1 receiving PCI without high-risk features, OAC plus clopidogrel is suggested for at least 1 month (BMS) or at least 3 months</p> <p>ii) In patients ≥ 65 years and CHADS₂ ≥ 1 receiving PCI with high-risk features, OAC, aspirin and clopidogrel are indicated up to 6 months, followed by OAC plus clopidogrel up to 12 months</p>	<p>Triple therapy is recommended to be as short as possible, in relation to bleeding risk, unless the risk of stent thrombosis/recurrence would not be too high. After triple therapy, dual therapy with OAC and P2Y12 inhibitor (preferably clopidogrel) should be continued up to 12 months after PCI.</p>
Rating of Evidence	<p>i) Strong Recommendation, Moderate-Quality of Evidence</p> <p>ii) Strong Recommendation, Low-Quality of Evidence</p>	<p>i) Weak Recommendation, Low-Quality of Evidence</p> <p>ii) Weak Recommendation, Low-Quality of Evidence</p> <p>iii) Weak Recommendation, Low-Quality of Evidence</p>	<p>i) Weak Recommendation, Moderate-Quality of Evidence</p> <p>ii) Weak Recommendation, Moderate-Quality of Evidence</p>	Not rated
Use of NOACs	No specific recommendation done.	NOACs are indicated equally to VKAs	A NOAC is preferred over VKA	A NOAC is preferred over VKA
Rating of	-	Weak Recommendation,	Weak Recommendation,	Not rated

Evidence

Low-Quality of Evidence

Moderate-Quality of Evidence

-
- 1 **Legend:** ACS= Acute Coronary Syndrome; PCI= Percutaneous Coronary Intervention; for other acronyms please see previous
 - 2 tables legends.
 - 3

ACCEPTED MANUSCRIPT

1 **Table 5:** Oral Anticoagulation Management in Patients Undergoing Ablation or Cardioversion Procedure

	CCS	ESC	APHRS
Year	2016	2016	2017
Ablation Procedure	OAC should be continued after AF surgical ablation according to CCS algorithm	<ul style="list-style-type: none"> i) All patients should receive OAC for at least 8 weeks after catheter ablation ii) OAC should be continued indefinitely after successful catheter ablation in patients at high risk of stroke iii) Continuation of OAC with VKAs or NOACs during procedure is recommended 	<ul style="list-style-type: none"> i) NOACs can be safe and effective alternatives to VKAs for periprocedural anticoagulation ii) OAC should be continued for at least 3 weeks before procedure in patients with at least 48 H of AF iii) OAC should be continued for at least 2 months after ablation, and longer in those patients with high risk of stroke
Rating of Evidence	Strong Recommendation, Moderate-Quality of Evidence	<ul style="list-style-type: none"> i) Class IIa, Level B ii) Class IIb, Level C iii) Class IIb, Level B (VKAs) or Level C (NOACs) 	Not rated
Cardioversion Procedure	OAC should be prescribed for 3 weeks before cardioversion and at least 4 weeks after. If AF recurs OAC should be prescribed on the basis of the CCS algorithm. If SR is achieved, decision on continuing OAC after 4 weeks of treatment should be based on risk of stroke and upon expert consultation	<ul style="list-style-type: none"> i) Effective anticoagulation is recommended for at least 3 weeks before cardioversion ii) Anticoagulation with heparin or NOAC should be initiated before every cardioversion procedure iii) In patients without stroke risk factors anticoagulation is recommended for 4 weeks. In those at risk of stroke anticoagulation should be continued long-term after procedure iv) Perform TEE is recommended as an alternative to OAC v) If with TEE a thrombus is identified 3 	<ul style="list-style-type: none"> i) Anticoagulation is needed 3 weeks before and 4 weeks after cardioversion procedure ii) In patients undergoing TEE, if thrombus is identified OAC is needed for at least 4 weeks and repeat TEE to ensure thrombus resolution ii) After cardioversion long-term OAC is needed in patients with high risk of stroke iv) For OAC in patients undergoing cardioversion both VKAs and NOACs can be considered

Rating of Evidence	Strong Recommendation, Moderate-Quality of Evidence	weeks OAC is recommended i) Class I, Level B ii) Class IIa, Level B iii) Class I, Level B iv) Class I, Level B v) Class I, Level C	Not rated
--------------------	--	---	-----------

1

2

ACCEPTED MANUSCRIPT


1 **Table 5 (continued):** Oral Anticoagulation Management in Patients Undergoing Ablation or Cardioversion Procedure


	NHFA/CSANZ	ACCP	CCS	KHRS
Year	2018	2018	2018	2018
Ablation Procedure	Uninterrupted OAC is recommended for patients undergoing catheter ablation	i) OAC with VKA, dabigatran or rivaroxaban is recommended for patients undergoing ablation ii) After ablation long-term OAC should be prescribed on the basis of thromboembolic risk profile	Use of uninterrupted OAC, either with NOACs or VKAs is recommended	i) Uninterrupted OAC is recommended for patients undergoing catheter ablation ii) OAC after ablation should be continued for at least 2 months iii) After 2 months, long-term OAC should be decided on patient's stroke risk
Rating of Evidence	Strong Recommendation, Moderate-Quality of Evidence	i) Weak Recommendation, Low-Quality of Evidence ii) Weak Recommendation, Low-Quality of Evidence	Weak Recommendation, Moderate-Quality of Evidence	Not rated
Cardioversion Procedure	i) OAC for 3 weeks is recommended (or TEE to document absence of left atrium thrombus) before cardioversion procedure ii) OAC is recommended for at least 4 weeks after cardioversion procedure	i) In patients with AF for 48H or more OAC with VKAs or NOACs is recommended at least 3 weeks before cardioversion or TEE approach with abbreviated OAC treatment ii) In patients with 48H or less AF or hemodynamic instability, parenteral anticoagulation should be started as soon as possible before procedure and continued for at least 4 weeks	i) Patients planned to receive cardioversion should receive OAC for 3 weeks before procedure ii) 3 weeks OAC treatment can be waived if AF is <12 with no recent stroke or within 12 and 48 hours and there is no substantial stroke risk iii) OAC is recommended to be	i) OAC is recommended for at least 3 weeks before cardioversion ii) After procedure OAC is recommended for at least for 4 weeks in patients without stroke risk factors. In patients at risk of stroke, long-term OAC is recommended iii) Anticoagulation with heparin or NOAC should be initiated as soon as possible before every

		iii) After cardioversion, OAC with VKAs or NOACs should be continued for at least 4 weeks. Continuing OAC beyond 4 weeks should be based on general OAC prescription decision making	continued for at least 4 weeks iv) TEE can be considered as an alternative to OAC v) Both NOACs and heparin/VKAs strategies can be used vi) OAC continuation after 4 weeks should be decided on the basis of CCS algorithm	cardioversion procedure iv) If a TEE identify a thrombus in left atrium, effective anticoagulation is recommended for at least 3 weeks
Rating of Evidence	i) Strong Recommendation, Low-Quality of Evidence	i) Strong Recommendation, Moderate-Quality of Evidence ii) Weak Recommendation, Low-Quality of Evidence iii) Strong Recommendation, Moderate-Quality of Evidence	i) Strong Recommendation, Moderate-Quality of Evidence ii) Weak Recommendation, Low-Quality of Evidence iii) Weak Recommendation, Low-Quality of Evidence iv) Weak Recommendation, Moderate-Quality of Evidence v) Weak Recommendation, Low-Quality of Evidence vi) Strong Recommendation, Moderate-Quality of Evidence	i) Class I, Level B ii) Class I, Level B iii) Class IIa, Level B iv) Class I, Level C


1 **Legend:** SR= Sinus Rhythm; TEE= Trans-Esophageal Echocardiography; for other acronyms please see previous tables legends.

2





ACCEPTED MANUSCRIPT



ACCEPTED MANUSCRIPT